Investment analysts at StockNews.com assumed coverage on shares of Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) in a research note issued on Wednesday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
Other equities analysts have also recently issued reports about the company. HC Wainwright reiterated a "buy" rating and set a $6.50 target price on shares of Nektar Therapeutics in a research note on Thursday, March 13th. Jefferies Financial Group raised Nektar Therapeutics from a "hold" rating to a "buy" rating and increased their price objective for the company from $1.00 to $2.00 in a research report on Friday, April 11th. Oppenheimer raised Nektar Therapeutics from a "market perform" rating to an "outperform" rating and set a $6.00 target price for the company in a research report on Friday, March 14th. B. Riley began coverage on shares of Nektar Therapeutics in a report on Wednesday, January 8th. They set a "buy" rating and a $4.00 price target on the stock. Finally, William Blair reissued a "market perform" rating on shares of Nektar Therapeutics in a report on Thursday, March 13th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Nektar Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $4.50.
Check Out Our Latest Stock Report on NKTR
Nektar Therapeutics Stock Up 4.9 %
Shares of NASDAQ:NKTR traded up $0.03 on Wednesday, hitting $0.64. 1,993,893 shares of the company traded hands, compared to its average volume of 1,804,127. The company has a market cap of $118.44 million, a PE ratio of -0.76 and a beta of 0.69. The stock has a 50 day simple moving average of $0.77 and a 200-day simple moving average of $0.97. Nektar Therapeutics has a 52 week low of $0.43 and a 52 week high of $1.93.
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last released its quarterly earnings data on Wednesday, March 12th. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of ($0.18) by $0.33. The business had revenue of $29.18 million during the quarter, compared to analyst estimates of $36.65 million. Nektar Therapeutics had a negative net margin of 180.70% and a negative return on equity of 173.28%. As a group, sell-side analysts anticipate that Nektar Therapeutics will post -0.72 earnings per share for the current year.
Institutional Trading of Nektar Therapeutics
Large investors have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC bought a new position in Nektar Therapeutics in the first quarter worth approximately $41,000. Rhumbline Advisers lifted its position in Nektar Therapeutics by 23.3% during the first quarter. Rhumbline Advisers now owns 221,761 shares of the biopharmaceutical company's stock valued at $151,000 after purchasing an additional 41,948 shares in the last quarter. Wellington Management Group LLP grew its holdings in Nektar Therapeutics by 10.4% during the fourth quarter. Wellington Management Group LLP now owns 522,409 shares of the biopharmaceutical company's stock valued at $486,000 after purchasing an additional 49,319 shares during the period. Mackenzie Financial Corp increased its position in Nektar Therapeutics by 801.4% in the fourth quarter. Mackenzie Financial Corp now owns 469,769 shares of the biopharmaceutical company's stock worth $437,000 after buying an additional 417,651 shares in the last quarter. Finally, US Asset Management LLC bought a new position in shares of Nektar Therapeutics in the fourth quarter worth about $31,000. 75.88% of the stock is currently owned by institutional investors.
About Nektar Therapeutics
(
Get Free Report)
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.
Featured Articles
Before you consider Nektar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nektar Therapeutics wasn't on the list.
While Nektar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
